{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:48:44Z","timestamp":1782118124479,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hydroxyurea (HU) is a first-line oral cytoreductive agent for selected patients with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), due to its efficacy and tolerability. Although cutaneous ulceration is a recognized complication of long-term HU exposure, HU-associated digital gangrene is rare, and upper-extremity involvement in PV has not previously been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We describe the first case of HU-associated digital gangrene in a patient with PV. A 72-year-old man with well-controlled Janus kinase 2 (JAK2)\u2013positive PV, treated with HU for more than a decade, developed painless dry gangrene of the right index and middle fingers. Vascular imaging showed no significant arterial occlusion or embolic source. Hematologic parameters remained within target ranges, and the workup for autoimmune disease, infection, and hypercoagulability was unremarkable. HU was discontinued, and the ischemia stabilized without surgical intervention. With no alternative etiology identified, delayed HU-associated vasculopathy was suspected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our literature review identified three previously reported cases of HU-associated digital gangrene, though limited to the lower extremities \u2013 two in chronic myeloid leukemia (CML) and one in sickle cell disease (SCD). In each case, gangrene developed after prolonged HU exposure, alternative etiologies were not substantiated, and stabilization or clinical improvement followed HU withdrawal. The present case aligns with this pattern while extending the reported phenotype to well-controlled PV and upper-extremity digits. Given the small number of reported cases, the pathophysiology remains incompletely defined and is largely extrapolated from studies of more frequently described HU-associated ulceration, histopathologic reports of HU-related tissue injury, and in vitro studies of HU effects on endothelial and circulating cells. Plausible mechanisms include cumulative endothelial injury, localized thrombo-occlusive microvascular dysfunction, impaired vascular and cutaneous repair, and interaction with PV-related microvascular susceptibility. Clinicians should include HU-associated vasculopathy in the differential diagnosis of otherwise unexplained digital ischemia, as prompt drug cessation may limit progression and improve digit salvage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-026-00887-0","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:06:19Z","timestamp":1781888779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9280-1019","authenticated-orcid":false,"given":"Angela","family":"Misic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadi","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"887_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/genes7110099","volume":"7","author":"A Singh","year":"2016","unstructured":"Singh A, Xu Y-J. cell killing mechanisms of hydroxyurea. Genes (Basel). 2016;7:99. https:\/\/doi.org\/10.3390\/genes7110099.","journal-title":"Genes"},{"key":"887_CR2","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","volume":"35","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35:3339\u201351. https:\/\/doi.org\/10.1038\/s41375-021-01401-3.","journal-title":"Leukemia"},{"key":"887_CR3","doi-asserted-by":"publisher","unstructured":"Sirieix M-E, Debure C, Baudot N, Dubertret L, Roux M-E, Morel P, et al. Leg ulcers and hydroxyurea: forty-one cases. arch dermatol [Internet]. Arch Dermatol. 1999 [cited 2025 May 22];135. https:\/\/doi.org\/10.1001\/archderm.135.7.818.","DOI":"10.1001\/archderm.135.7.818"},{"key":"887_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1067\/mjd.2002.120910","volume":"47","author":"N Aste","year":"2002","unstructured":"Aste N, Fumo G, Contu F, Aste N, Biggio P. Nail pigmentation caused by hydroxyurea: Report of 9 cases. J Am Acad Dermatol. 2002;47:146\u20137. https:\/\/doi.org\/10.1067\/mjd.2002.120910.","journal-title":"J Am Acad Dermatol"},{"key":"887_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","volume":"30","author":"RK Agrawal","year":"2014","unstructured":"Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in Sickle Cell Disease: Drug Review. Indian J Hematol Blood Transfus. 2014;30:91\u20136. https:\/\/doi.org\/10.1007\/s12288-013-0261-4.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"887_CR6","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1503\/cmaj.081042","volume":"180","author":"J Dissemond","year":"2009","unstructured":"Dissemond J, Korber A. Hydroxyurea-induced ulcers on the leg. Can Med Assoc J CMA Joule Inc. 2009;180:1132\u20131132. https:\/\/doi.org\/10.1503\/cmaj.081042.","journal-title":"Can Med Assoc J CMA Joule Inc"},{"issue":"200002","key":"887_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/(sici)1096-8652","volume":"63","author":"N Yasuda","year":"2000","unstructured":"Yasuda N, Ohmori S, Usui T. Hydroxyurea-Induced gangrene of the toes in a patient with chronic myelogenous leukemia. Am J Hematol Wiley. 2000;63(200002):103\u20134. https:\/\/doi.org\/10.1002\/(sici)1096-8652.)63:2%253C103::aid-ajh11%253E3.0.co;2-n.","journal-title":"Am J Hematol Wiley"},{"key":"887_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.jfas.2013.07.003","volume":"52","author":"VK Shanmugam","year":"2013","unstructured":"Shanmugam VK, McNish S, Shara N, Hubley KJ, Kallakury B, Dunning DM, et al. Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(\u00ae)). J Foot Ankle Surg Off Publ Am Coll Foot Ankle Surg. 2013;52:781\u20135. https:\/\/doi.org\/10.1053\/j.jfas.2013.07.003.","journal-title":"J Foot Ankle Surg Off Publ Am Coll Foot Ankle Surg"},{"key":"887_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00277-002-0505-0","volume":"81","author":"E Leo","year":"2002","unstructured":"Leo E, Kr\u00e4mer A, Hochhaus A, Krasniqi F, Hehlmann R, Ho A. Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy. Ann Hematol. 2002;81:467\u20139. https:\/\/doi.org\/10.1007\/s00277-002-0505-0.","journal-title":"Ann Hematol Springer Sci Bus Media LLC"},{"key":"887_CR10","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00277-024-05732-w","volume":"103","author":"G Bhangu","year":"2024","unstructured":"Bhangu G, Uminski K, Roessner C, Goodyear D, Sale T, Rydz N. Dry gangrene in a patient with sickle cell disease on hydroxyurea: a case report. Ann Hematol Springer Sci Bus Media LLC. 2024;103:3277\u20139. https:\/\/doi.org\/10.1007\/s00277-024-05732-w.","journal-title":"Ann Hematol Springer Sci Bus Media LLC"},{"key":"887_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jtv.2013.08.002","volume":"22","author":"F Quattrone","year":"2013","unstructured":"Quattrone F, Dini V, Barbanera S, Zerbinati N, Romanelli M. Cutaneous ulcers associated with hydroxyurea therapy. J Tissue Viability Elsevier BV. 2013;22:112\u201321. https:\/\/doi.org\/10.1016\/j.jtv.2013.08.002.","journal-title":"J Tissue Viability Elsevier BV"},{"key":"887_CR12","doi-asserted-by":"publisher","unstructured":"Michalak J, Simman R, Oostra D. A Case of thrombotic vasculopathy in the setting of high-dose hydroxyurea use. Wounds Compend Clin Res Pract. HMP Communications, LLC; 2021;34:E79\u201384. https:\/\/doi.org\/10.25270\/wnds\/2021.e7984.","DOI":"10.25270\/wnds\/2021.e7984"},{"key":"887_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.mvr.2014.05.009","volume":"94","author":"FCM Lopes","year":"2014","unstructured":"Lopes FCM, Ferreira R, Albuquerque DM, Silveira AAA, Costa R, Soares R, et al. In vitro and in vivo anti-angiogenic effects of hydroxyurea. Microvasc Res. 2014;94:106\u201313. https:\/\/doi.org\/10.1016\/j.mvr.2014.05.009.","journal-title":"Microvasc Res"},{"key":"887_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.tpj.6500176","volume":"3","author":"M Brun","year":"2003","unstructured":"Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J Springer Sci Bus Media LLC. 2003;3:215\u201326. https:\/\/doi.org\/10.1038\/sj.tpj.6500176.","journal-title":"Pharmacogenomics J Springer Sci Bus Media LLC"},{"key":"887_CR15","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood.V91.10.3986","volume":"91","author":"KG Engstr\u00f6m","year":"1998","unstructured":"Engstr\u00f6m KG, L\u00f6fvenberg E. Treatment of Myeloproliferative Disorders With Hydroxyurea: Effects on Red Blood Cell Geometry and Deformability. Blood. 1998;91:3986\u201391. https:\/\/doi.org\/10.1182\/blood.V91.10.3986.","journal-title":"Blood"},{"key":"887_CR16","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3324\/haematol.2017.182303","volume":"103","author":"M Brusson","year":"2018","unstructured":"Brusson M, De Grandis M, Cochet S, Bigot S, Marin M, Leduc M, et al. Impact of hydroxycarbamide and interferon-\u03b1 on red cell adhesion and membrane protein expression in polycythemia vera. Haematologica. 2018;103:972\u201381. https:\/\/doi.org\/10.3324\/haematol.2017.182303.","journal-title":"Haematologica"},{"key":"887_CR17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0040-8166(92)90020-8","volume":"24","author":"RM Greco","year":"1992","unstructured":"Greco RM, Ehrlich HP. Differences in cell division and thymidine incorporation with rat and primate fibroblasts in collagen lattices. Tissue Cell. 1992;24:843\u201351. https:\/\/doi.org\/10.1016\/0040-8166(92)90020-8.","journal-title":"Tissue Cell"},{"key":"887_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1046\/j.1365-2141.2001.03092.x","volume":"115","author":"T Neunteufl","year":"2001","unstructured":"Neunteufl T, Heher S, Stefenelli T, Pabinger I, Gisslinger H. Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol Wiley. 2001;115:354\u20139. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03092.x.","journal-title":"Br J Haematol Wiley"},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.blre.2014.12.002","volume":"29","author":"MH Kroll","year":"2015","unstructured":"Kroll MH, Michaelis LC, Verstovsek S. Mechanisms of thrombogenesis in polycythemia vera. Blood Rev Elsevier BV. 2015;29:215\u201321. https:\/\/doi.org\/10.1016\/j.blre.2014.12.002.","journal-title":"Blood Rev Elsevier BV"},{"key":"887_CR20","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol Wiley. 2023;98:1465\u201387. https:\/\/doi.org\/10.1002\/ajh.27002.","journal-title":"Am J Hematol Wiley"},{"key":"887_CR21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/ijms25031417","volume":"25","author":"JMP Grenier","year":"2024","unstructured":"Grenier JMP, El Nemer W, De Grandis M. Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia. Int J Mol Sci MDPI AG. 2024;25:1417. https:\/\/doi.org\/10.3390\/ijms25031417.","journal-title":"Int J Mol Sci MDPI AG"},{"key":"887_CR22","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2024.0133","author":"J Dissemond","year":"2024","unstructured":"Dissemond J, Placke J-M, Moelleken M, Kr\u00f6ger K. The differential diagnosis of leg ulcers. Dtsch \u00c4rztebl Int [Internet]. 2024. https:\/\/doi.org\/10.3238\/arztebl.m2024.0133. [cited 2025 May 29].","journal-title":"Dtsch \u00c4rztebl Int [Internet]"},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"rkae153","DOI":"10.1093\/rap\/rkae153","volume":"9","author":"S Kubota","year":"2024","unstructured":"Kubota S, Kobayashi Y, Hanai S, Nakagomi D. Rapidly progressive digital necrosis in polyarteritis nodosa. Rheumatol Adv Pract. 2024;9:rkae153. https:\/\/doi.org\/10.1093\/rap\/rkae153.","journal-title":"Rheumatol Adv Pract"},{"key":"887_CR24","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s10067-020-05399-4","volume":"40","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Pauling JD. Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders. Clin Rheumatol. 2021;40:2457\u201365. https:\/\/doi.org\/10.1007\/s10067-020-05399-4.","journal-title":"Clin Rheumatol"},{"key":"887_CR25","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/rheumatology\/keac623","volume":"62","author":"B Chevet","year":"2023","unstructured":"Chevet B, Cornec D, Casal Moura M, Cornec-Le Gall E, Fervenza FC, Warrington KJ, et al. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. Rheumatology. 2023;62:1787\u2013803. https:\/\/doi.org\/10.1093\/rheumatology\/keac623.","journal-title":"Rheumatology"},{"key":"887_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","volume":"2016","author":"S Berentsen","year":"2016","unstructured":"Berentsen S. Cold agglutinin disease. Hematology. Am Soc Hematol. 2016;2016:226\u201331. https:\/\/doi.org\/10.1182\/asheducation-2016.1.226.","journal-title":"Am Soc Hematol"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00887-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00887-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00887-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:06:45Z","timestamp":1782115605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00887-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00887-0","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Per the University of California, Los Angeles (UCLA) Office of the Human Research Protection Program guidance, this manuscript represents a retrospective case report describing the clinical course of a single patient (\u2264\u20093 records), reported with de-identified data; therefore, UCLA Institutional Review Board review was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent for publication of this case report and any accompanying images was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}